Get the Stockscreener App
13.18
0.04%
0.010
Takeda Pharmaceutical Co Adr stock is traded at $13.18, with a volume of 740.56K.
It is up +0.04% in the last 24 hours and down -1.53% over the past month.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
See More
Previous Close:
$13.17
Open:
$13.11
24h Volume:
740.56K
Relative Volume:
0.43
Market Cap:
$41.58B
Revenue:
$30.27B
Net Income/Loss:
$1.93B
P/E Ratio:
29.68
EPS:
0.444
Net Cash Flow:
$3.45B
1W Performance:
-1.38%
1M Performance:
-1.53%
6M Performance:
+2.29%
1Y Performance:
-6.23%
1-Day Range:
$13.09
$13.19
1-Week Range:
$12.98
$13.37
52-Week Range:
$12.57
$15.08
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
13.17 | 41.58B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
ZTS
Zoetis Inc
|
164.65 | 74.13B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.74 | 43.93B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.31 | 25.41B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.39 | 14.57B | 15.05B | -883.30M | 1.89B | -0.74 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-19-22 | Upgrade | Cowen | Market Perform → Outperform |
| Oct-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-19 | Initiated | Cowen | Market Perform |
| Aug-15-19 | Downgrade | Daiwa Securities | Outperform → Neutral |
View All
Takeda Pharmaceutical Co Adr Stock (TAK) Latest News
Burkitt Lymphoma Global Clinical Trials Review 2024: Clinical Trials by Region, Country, Trial Status, Trial Phase, Sponsor Type and End Point Status - GlobeNewswire Inc.
Weekly Upgrades and Downgrades - InvestorPlace
Saudi Arabia Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Dr. Kevan Jacobson and Dr. Genelle Lunken Awarded $1M Pioneer Grant for Transformative Pediatric Research in Inflammatory Bowel Disease - Quantisnow
Things To Consider Before You Buy Takeda Pharmaceutical Co ADR (NYSE: TAK) - Stocks Register
Capital One Financial Corp (NYSE: COF): Overvalued In Comparison To Others? - Stocks Register
Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies - MSN
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform - Quantisnow
Australia Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Denmark Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Italy Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
UK Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
South Africa Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading - MSN
Earnings call: Takeda reports robust H1 growth, revises full-year guidance - Investing.com Australia
Earnings call: Takeda reports robust H1 growth, revises full-year guidance By Investing.com - Investing.com South Africa
Torm Plc (NASDAQ: TRMD): Getting A Free Pass? - Stocks Register
What Analysts Were Expecting After Checkpoint Therapeutics Inc (NASDAQ: CKPT) rose 2.03% - Stocks Register
Spain Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Thailand Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Dyne Therapeutics Inc (DYN) gets rating Reiterated from Chardan Capital Markets - Knox Daily
W & T Offshore Inc (WTI) receives a Buy rating from Stifel - Knox Daily
JP Morgan Upgrades Mister Car Wash Inc (MCW) to an Overweight from a Neutral - Knox Daily
BofA Securities upgrades Takeda Pharmaceutical Co ADR (TAK) rating to a Buy - Knox Daily
What Did We Find About Insider Trading At Ovintiv Inc (NYSE: OVV)? - Stocks Register
Mizuho analysts downgrades a Neutral rating for Squarespace Inc (SQSP) - Knox Daily
Barclays gives an Equal weight recommendation for Kilroy Realty Corp. (KRC) - Knox Daily
Microchip Technology, Inc. (MCHP) receives a Hold rating from Truist - Knox Daily
Cantor Fitzgerald’s latest rating for EBAY stock - Knox Daily
Watch this stock’s price performance: Takeda Pharmaceutical Co ADR (NYSE:TAK) - US Post News
North America Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research
Mexico Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research
China Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research
Italy Retinal Disorder Treatment Market Size & Outlook, 2030 - Grand View Research
Takeda Pharmaceutical Co Adr Stock (TAK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):